In contradistinction to the 200 subjects randomized in ORBITA, PCI has been performed in millions of patients; despite significant efforts improving the clinical appropriateness of PCI, 3 some have argued that the performance of PCI in SIHD is far less controlled outside of trials, and its use has outstripped the evidence base in support of it. 4 The tension inherent in this paradox is readily apparent when contrasting the differences between the original ORBITA study publication versus the way the trial was publicly discussed and debated. 5 In the wake of the sensationalistic coverage of the trial, it was clear that for detractors of PCI, this mechanistic trial was made to be something it is not: the final word for the limited role of PCI across a spectrum of SIHD patient presentations and disease subtypes. For some on the opposite end of the spectrum, the trial has been summarily and unfairly dismissed.
Both of these antithetical viewpoints miss the mark. ORBITA serves as a reminder that difficult trials can be done with perseverance, 6 and that the incremental symptomatic benefits of blinded PCI among patients with single-vessel disease on truly maximal medical therapy are modest at 6 weeks after the procedure. Although ORBITA did not have a comparator arm of medical therapy without sham PCI, the trial also affirms that the placebo effects of a sham PCI (admittedly within the trial setting) are even more modest in the same population, as evidenced by no absolute increase in exercise duration or changes in ischemic testing and small improvements in quality of life.
1 So how can we reconcile these findings with that of numerous other observations that have demonstrated more marked symptomatic improvements with unblinded PCI over medical therapy on less antianginal therapy? [7] [8] [9] By virtue of being a smaller trial with the dexterity to allow for the collection of multiple mechanistic end points, ORBITA affords the ability to study these end points to determine which ones might be most sensitive to detect physiologi-cal treatment effects of PCI. Although of course subject to statistical limitations related to testing multiple comparisons, this careful examination of end points is still quite helpful because the space of sham-controlled trials of PCI was nonexistent before ORBITA.
In this issue of Circulation, the ORBITA investigators 10 expand on their initial findings in 2 important ways. First, addressing legitimate critiques of the primary analyses that comparisons of within-group changes from baseline were not adjusted for differences between the treatment groups (eg, the striking 38-second better exercise time before randomization in the PCI group), the authors have redone all primary analyses of the trial with adjustments for baseline differences. The primary study findings are largely preserved, with a few notable caveats. The change in exercise treadmill time between arms is now 20.7 seconds (95% confidence interval of -4.0 to 45.5 seconds) greater with PCI compared with sham, further raising the question of whether the trial would have been "positive" had it enrolled more patients or had it been conducted among patients on less intensive antianginal therapy. In point of fact, this declaration of "positivity" or "negativity" is not clinically relevant because the (adjusted) effect size with its confidence interval provides the most credible estimate of the expected magnitude of treatment effect among patients similar to those enrolled in ORBITA. Nonetheless, in the conventional all-or-none frequentist approach to the literature, trials that meet significance for primary end points are interpreted differently than those that do not, so it is unfortunate that a more precise estimate of treatment effect was not achieved.
The new analyses additionally reaffirm the substantial improvement of ischemia as measured by dobutamine stress echocardiography among patients randomized to PCI (without such effects among sham). In conjunction, these analyses provide new insights related to the relief of anginal symptoms. After the aggressive medical titration protocol in ORBITA, the anginal burden was quite low. For example, baseline anginal frequency as assessed by the SAQ (Seattle Anginal Questionnaire) was 79 with PCI versus 75 with sham (higher numbers equate with less angina). A score of ≈80 roughly equates to angina occurring/requiring nitroglycerin once a week or less.
Further, ≈15% of the PCI group and 20% of the sham group were free of angina. After randomization, the odds of improvement in anginal frequency assessed through an ordinal interpretation of the SAQ scale was nominally greater with PCI over sham, and 50% of patients with PCI were angina-free compared with only 32% among sham. For perspective, these findings are similar to those observed in both ACME (Angioplasty Compared to Medicine) (≈50% freedom from angina with PCI and ≈20% with medical therapy at 1 month) and COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) (42% versus 33%, respectively).
Beyond anginal frequency, other quality-of-life indices improved overall but were not appreciably different between the 2 treatment groups. These similarities notwithstanding, as the authors state, "The most binary of patient-reported changes is the absence versus presence of symptoms," 10 and blinded PCI resulted in unequivocal improvements in this patient-oriented end point. ORBITA of course cannot answer whether these symptoms would remain differentially improved in favor of PCI over time or whether these findings would be maintained if patients had been withdrawn from antianginal therapies, as in clinical practice. However, in the context of prior randomized trials demonstrating improved anginal symptoms with PCI on less antianginal therapy, [7] [8] [9] these new findings from ORBITA should be strongly considered in a patient-centered approach to clinical care. Symptomatic patients do not pursue therapies with a 6-week goal in mind. For patients limited by their angina, the conventional alternative to coronary revascularization is a commitment to long-term therapy with multiple antianginal agents that may have side effects and create issues relating to polypharmacy. For some patients this might be a reasonable choice, but for many patients it is not.
The second major contribution of the present analysis is further examination of the blinded invasive physiological data obtained within ORBITA. One of the most strident critiques of the trial relates to the inclusion of patients with a range of physiologies characterized as nonflow limiting by conventionally assessed invasive pressure wire measurements. Given the de facto mechanism of action of PCI (improvement of coronary flow through relief of epicardial hemodynamic obstruction), it is fair to state that the statistical power of the overall study to detect this effect of PCI was attenuated due to the inclusion of patients without pronounced limitations to flow at the time of randomization. However, in their study design, the ORBITA investigators sought to replicate real-world practice, in which invasive physiological testing is used in only a small proportion of cases. 12 By incorporating blinded physiological assessment, the investigators allowed further insights into the relationship between baseline physiology and the ascertained ischemia and angina end points to be explored.
In a series of analyses presented herein, differences between PCI and sham as assessed by dobutamine stress echocardiography were progressively more pronounced among patients with increasingly abnormal physiology (lower fractional flow reserve or instantaneous wave-free ratio) at baseline, with a highly significant interaction term. It is therefore clear (and intuitive) that PCI reduces ischemia the most among those with greater degrees of hemodynamic obstruction to flow. However, the treatment effects of PCI versus sham on all other assessed end points were not modified by base-line physiology. The authors have depicted these interactions graphically as well as through presentation of the results using a variety of dichotomous cut points so as to allow a more granular look at the data. Some may view these results as a repudiation of the use of coronary physiology to guide the use of PCI for patients with SIHD; that is an overinterpretation of these results. The actual number of patients with normal-range physiology is low, limiting the accuracy of observations such as numerically greater exercise time differences (and freedom from angina) between PCI and sham among patients with normal-range physiology. Additionally, all interaction terms (with the exception of the term for the dobutamine stress echocardiography findings) are nonsignificant, suggesting consistency of the primary study findings across the range of physiology observed within the trial. The purist view is that the absence of detectable effect modification by coronary physiology largely confirms the primary ORBITA results. As stated by the authors, the lack of large observed treatment effects on multiple study end points further limits the power to detect differences among physiological substrata.
Nonetheless, these observations illustrate that the clearly demonstrated physiological effect of PCI over sham as assessed by fractional flow reserve and instantaneous wave-free ratio does not easily translate into downstream clinical observations within the trial, highlighting the subjective and multifactorial nature of anginal symptoms. However, in a patient-centered approach to care, the combination of presenting symptoms (with response to therapy), preprocedural ischemic testing, and baseline angiography can be further positively informed by the judicious use of in-laboratory physiological testing to attempt to more objectively assess the hemodynamic and functional significance of a coronary stenosis. 13 This is especially relevant to clinicians presented with equivocal or discordant findings between noninvasive testing and angiography. The ultimate clinical goal within the catheterization laboratory for patients without prognostically significant disease is to be able to more reliably predict the probability of a patient feeling better after a coronary revascularization procedure that aims to relieve the hemodynamic impact of an obstructive epicardial stenosis. These data emphasize that epicardial coronary physiology is not the sole determinant of clinical symptom relief, particularly among patients whose angina is well controlled on intensive medical therapy.
The fundamental charge of ORBITA to clinicians taking care of the full spectrum of patients with SIHD is to accept the 6-week results of a blinded 200-patient trial conducted among maximally managed patients with single-vessel disease while also contextualizing these results within the construct of other randomized trials, observational data, and our clinical experience with patients with greater symptom and disease burdens.
14 Responsible and thoughtful caregivers recognize both the strengths and limitations of new evidence-based medicine but are humble enough to dynamically adapt their approach as new evidence (and new patients) come along. Within that more nuanced rubric, the ORBITA trial teaches important lessons that will ultimately transcend all controversies.
